PharmacoEconomics

ISSNs: 1170-7690, 1179-2027

Additional searchable ISSN (Electronic): 1179-2027

Adis International Ltd

Scopus rating (2018): CiteScore 3.65 SJR 1.942 SNIP 1.608

Journal

Publications

1 - 25 out of 25Page size: 25
RSS feed of this list
  1. 2019

  2. Tisagenlecleucel for the Treatment of Relapsed or Refractory B-cell Acute Lymphoblastic Leukaemia in People Aged up to 25 Years: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

    Walton, M., Sharif, S., Simmonds, M., Claxton, L. & Hodgson, R., 13 Apr 2019

    Article in PharmacoEconomics

  3. The Clinical and Cost-Effectiveness of Inotuzumab Ozogamicin for the Treatment of Adult Relapsed or Refractory B-cell Acute Lymphoblastic Leukaemia: an Evidence Review Group Evaluation of a NICE Single Technology Appraisal: Inotuzumab for the treatment of adult R/R B-cell ALL: an ERG perspective

    Cox, E. M., Wade, R. F., Peron, M. M. G., Dietz, K. C., Eastwood, A. J., Palmer, S. J. & Griffin, S., 19 Mar 2019

    Review article in PharmacoEconomics

  4. Correction to: Different Methods for Modelling Severe Hypoglycaemic Events: Implications for Effectiveness, Costs and Health Utilities

    Keeney, E., Dawoud, D. & Dias, S., 9 Mar 2019

    Article in PharmacoEconomics

  5. An educational review about using cost data for the purpose of cost-effectiveness analysis

    Franklin, M., Lomas, J. R. S., Walker, S. M. & Young, T., 23 Jan 2019, (Accepted/In press)

    Article in PharmacoEconomics

  6. 2018

  7. Sensitivity Analysis for Not-at-Random Missing Data in Trial-Based Cost-Effectiveness Analysis: A Tutorial

    Leurent, B., Gomes, M., Faria, R., Morris, S., Grieve, R. & Carpenter, J. R., Aug 2018

    Article in PharmacoEconomics

  8. Discounting in Economic Evaluations

    Attema, A. E., Brouwer, W. B. F. & Claxton, K., 19 May 2018

    Review article in PharmacoEconomics

  9. Cost effectiveness thresholds: the past, the present and the future

    Thokala, P., Ochalek, J. M., Leech, A. & Tong, T., 9 Feb 2018

    Article in PharmacoEconomics

  10. 2017

  11. Ustekinumab for Treating Moderately to Severely Active Crohn's Disease after Prior Therapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

    Hodgson, R., Walton, M., Biswas, M., Mebrahtu, T. & Woolacott, N., 30 Nov 2017

    Article in PharmacoEconomics

  12. Crizotinib for Untreated Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

    Morgan, P. J., Woolacott, N. F., Biswas, M., Mebrahtu, T., Harden, M. & Hodgson, R., 24 Mar 2017

    Review article in PharmacoEconomics

  13. A Review of Ruxolitinib for the Treatment of Myelofibrosis: A Critique of the Evidence

    Wade, R. F., Hodgson, R., Biswas, M., Harden, M. & Woolacott, N. F., Feb 2017

    Article in PharmacoEconomics

  14. 2016

  15. Simulation Modelling in Ophthalmology: Application to Cost Effectiveness of Ranibizumab and Aflibercept for the Treatment of Wet Age-Related Macular Degeneration in the United Kingdom

    Claxton, L., Hodgson, R., Malcom, W., Jacob, R. & Taylor, M., Oct 2016

    Article in PharmacoEconomics

  16. The Clinical and Cost Effectiveness of Vortioxetine for the Treatment of a Major Depressive Episode in Patients With Failed Prior Antidepressant Therapy: A Critique of the Evidence

    Lomas, J., Llewellyn, A., Soares, M., Simmonds, M., Wright, K., Eastwood, A. & Palmer, S., 1 Sep 2016

    Article in PharmacoEconomics

  17. Daclatasvir for the Treatment of Chronic Hepatitis C: A Critique of the Clinical and Economic Evidence

    Llewellyn, A., Faria, R., Woods, B., Simmonds, M., Lomas, J., Woolacott, N. & Griffin, S., 8 Jun 2016

    Article in PharmacoEconomics

  18. The Clinical and Cost Effectiveness of Ustekinumab for the Treatment of Psoriatic Arthritis: A Critique of the Evidence

    O'Connor, J., Rice, S., Smith, A., Rodgers, M., Lopez, R. R., Craig, D. & Woolacott, N., Apr 2016

    Article in PharmacoEconomics

  19. Using Linked Electronic Health Records to Estimate Healthcare Costs: Key Challenges and Opportunities

    Asaria, M., Grasic, K. & Walker, S., Feb 2016

    Article in PharmacoEconomics

  20. Apremilast for the Treatment of Moderate to Severe Plaque Psoriasis: A Critique of the Evidence

    Hinde, S., Wade, R., Palmer, S., Woolacott, N. & Spackman, E., 2016

    Article in PharmacoEconomics

  21. 2015

  22. Assessing the Value of New Treatments for Hepatitis C: Are International Decision Makers Getting this Right?

    Woods, B., Faria, R. & Griffin, S., 29 Dec 2015

    Article in PharmacoEconomics

  23. Reply to Roberts et al. CHEERS is Sufficient for Reporting Cost-Benefit Analysis, but May Require Further Elaboration

    Husereau, D., Drummond, M., Petrou, S., Greenberg, D., Mauskopf, J., Augustovski, F., Briggs, A. H., Moher, D., Loder, E. & Carswell, C., 28 May 2015

    Article in PharmacoEconomics

  24. The Economic Costs of Type 2 Diabetes: A Global Systematic Review

    Seuring, T., Archangelidi, O. & Suhrcke, M., 19 Mar 2015

    Article in PharmacoEconomics

  25. The Clinical and Cost Effectiveness of Aflibercept in Combination with Irinotecan and Fluorouracil-Based Therapy (FOLFIRI) for the Treatment of Metastatic Colorectal Cancer Which has Progressed Following Prior Oxaliplatin-Based Chemotherapy: a Critique of the Evidence

    Wade, R., Duarte, A., Simmonds, M., Rodriguez-Lopez, R., Duffy, S., Woolacott, N. & Spackman, E., 24 Jan 2015

    Article in PharmacoEconomics

  26. Ipilimumab for Previously Untreated Unresectable Malignant Melanoma: A Critique of the Evidence

    Giannopoulou, C., Sideris, E., Wade, R., Moe-Byrne, T., Eastwood, A. & McKenna, C., 2015

    Article in PharmacoEconomics

  27. 2014

  28. Objectivity and Equity: Clarity Required. A Response to Hill and Olson

    Paulden, M., O’Mahony, J. F., Culyer, A. J. & McCabe, C., Dec 2014

    Article in PharmacoEconomics

  29. Some inconsistencies in NICE’s consideration of social values

    Paulden, M., O’Mahony, J., Culyer, T. & McCabe, C., Nov 2014

    Article in PharmacoEconomics

  30. Bidirectional Citation Searching to Completion: An Exploration of Literature Searching Methods

    Hinde, S. & Spackman, E., 22 Aug 2014

    Article in PharmacoEconomics

  31. 2013

  32. Ruxolitinib for the Treatment of Myelofibrosis: A NICE Single Technology Appraisal

    Wade, R., Rose, M., Neilson, A. R., Stirk, L., Rodriguez-Lopez, R., Bowen, D., Craig, D. & Woolacott, N., 31 Aug 2013

    Article in PharmacoEconomics

Discover related content

Find related publications, people, projects, datasets and more using interactive charts.

View graph of relations

York staff: edit these data